within Pharmacolibrary.Drugs.ATC.J;

model J01FA05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.4,
    Cl             = 15 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 250 / 1000000,
    adminCount     = 1,
    Vd             = 0.025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008333333333333333,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Oleandomycin is a macrolide antibiotic historically used to treat bacterial infections caused by susceptible Gram-positive and some Gram-negative organisms. It was commonly used in the mid-20th century but is now largely obsolete and not approved for use in most countries due to the availability of safer and more effective alternatives and due to resistance and toxicity concerns.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters based on general macrolide class and limited historical clinical information; specific published pharmacokinetic studies on oleandomycin in humans are not available.</p><h4>References</h4><ol><li><p>Milanova, A, &amp; Lashev, L (2002). Pharmacokinetics of oleandomycin in dogs after intravenous or oral administration alone and after pretreatment with metamizole or dexamethasone. <i>Veterinary research communications</i> 26(1) 61–71. DOI:<a href=&quot;https://doi.org/10.1023/a:1013309922721&quot;>10.1023/a:1013309922721</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11860088/&quot;>https://pubmed.ncbi.nlm.nih.gov/11860088</a></p></li><li><p>Ludden, TM (1985). Pharmacokinetic interactions of the macrolide antibiotics. <i>Clinical pharmacokinetics</i> 10(1) 63–79. DOI:<a href=&quot;https://doi.org/10.2165/00003088-198510010-00003&quot;>10.2165/00003088-198510010-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3882305/&quot;>https://pubmed.ncbi.nlm.nih.gov/3882305</a></p></li><li><p>Wang, JS, et al., &amp; Zhou, HH (1997). Effect of troleandomycin on the pharmacokinetics of imipramine in Chinese: the role of CYP3A. <i>British journal of clinical pharmacology</i> 44(2) 195–198. DOI:<a href=&quot;https://doi.org/10.1046/j.1365-2125.1997.00649.x&quot;>10.1046/j.1365-2125.1997.00649.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9278210/&quot;>https://pubmed.ncbi.nlm.nih.gov/9278210</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J01FA05;
